Muge Akinci

Muge Akinci

Auto-generated profile, based on publicly available information

Muge Akinci

Department of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center, 630 West 168th Street, New York, NY 10032, United States

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2025 in The Journal Of Prevention of Alzheimer's Disease
Verified
Journal Article
Open access
PAPablo Aguilar-Dominguez
Pablo Aguilar-Dominguez
EPEleni Palpatzis
Eleni Palpatzis
MAMuge Akinci
Muge Akinci
ACAnna Canal-Garcia
Anna Canal-Garcia
JPJoana B. Pereira
Joana B. Pereira
EAEider M. Arenaza-Urquijo
Eider M. Arenaza-Urquijo
Psychiatric symptoms are increasingly recognized as early manifestations of Alzheimer's disease (AD). These symptoms may reflect or contribute to underlying neurobiological changes, including tau burden, which represents more advanced AD pathology. Understanding factors associated with tau burden may help identify individuals at elevated risk and improve early detection strategies. To investigate the temporal relationships between neuropsychiatric symptoms, demographic factors, and tau burden, by examining amyloid (Aβ)-dependent, -independent, and interactive associations. Retrospective cohort study. Alzheimer's Disease Neuroimaging Initiative. We included 681 participants without dementia (mean age = 71.2 years, 51.8 % female). The participants underwent tau PET scanning with prior amyloid PET and Neuropsychiatric Inventory (NPI) interview assessments clustered around three time periods relative to tau PET: closest (0 - 2 years), mid (3 - 5 years), and furthest (6 - 8 years). Linear regression analyses, adjusting for age and APOE ε4 alleles, examined associations of NPI scores, sex, education, and their Aβ-status interactions with tau burden. Higher total NPI scores up to 2 years prior to tau PET were associated with greater tau burden independently of Aβ status, whereas anxiety symptoms demonstrated an Aβ-dependent relationship with tau. (NPI: β=0.117, 95 % CI: 0.049 to 0.185, p=0.001, Anxiety: β=0.249, 95 % CI: 0.073 to 0.424, p=0.006). NPI measured up to 5 years prior to tau PET interacted with Aβ on tau burden (0-2 years: β=0.272, 95 % CI: 0.136 to 0.407, p<0.001, 3-5 years: β=0.336, 95 % CI: 0.127 to 0.544, p=0.002). Sex and education showed minimal associations with tau at uncorrected statistical levels. Neuropsychiatric symptoms were associated with tau burden up to two years before tau sampling, independently of Aβ, and interacted with Aβ status up to five years prior, suggesting that neuropsychiatric symptoms are related to tau in the short term and may represent manifestations of advancing AD pathology. Demographic factors showed minimal associations. These findings highlight the importance of evaluating neuropsychiatric and anxiety symptoms as potential indicators of increased tau pathology.

24 February 2026 in Alzheimer's & Dementia
Verified
Journal Article
Open access
PDF file
MAMuge Akinci
Muge Akinci
FAFroogh Aziz
Froogh Aziz
DGDiana Guzman
Diana Guzman
LCLina Cheung
Lina Cheung
JKJian X. Kong
Jian X. Kong
JLJosé A. Luchsinger
José A. Luchsinger
INTRODUCTION: The association of type 2 diabetes (T2D) treatment with Alzheimer's disease (AD) is unclear. We examined T2D treatment status in relation to amyloid beta (Aβ) burden and AD‐related downstream processes. METHODS: This cross‐sectional study included 546 cognitively unimpaired adults (mean age = 64.2 ± 3.2 years, 65% women), classified into normal glucose tolerance (NGT; hemoglobin A1c [HbA1c] < 5.7%), prediabetes/untreated T2D (HbA1c ≥ 5.7%), and treated T2D groups. Multiple regression analyses assessed group differences in Aβ ( 18 F‐florbetaben) and tau ( 18 F‐MK‐6240) positron emission tomography burden, magnetic resonance imaging–based AD signature cortical thickness, white matter hyperintensity (WMH) volume, and memory performance. RESULTS: Compared to the NGT group, prediabetes/untreated T2D had greater anterior/posterior cingulate and superior parietal cortex Aβ burden, whereas treated T2D had lower cortical thickness and greater WMHs, independent of demographics and apolipoprotein E ε4 status. No group differences were found in tau or memory outcomes. DISCUSSION: Prediabetes/untreated T2D, but not treated T2D, was associated with early Aβ deposition. Diabetes medications may mitigate brain Aβ burden.

1 February 2026
Verified
Journal Article
Open access
MAMuge Akinci
Muge Akinci
FAFroogh Aziz
Froogh Aziz
DGDiana Guzman
Diana Guzman
LCLina Cheung
Lina Cheung
JKJian X Kong
Jian X Kong
JLJosé A Luchsinger
José A Luchsinger
The association of type 2 diabetes (T2D) treatment with Alzheimer's disease (AD) is unclear. We examined T2D treatment status in relation to amyloid beta (Aβ) burden and AD-related downstream processes. This cross-sectional study included 546 cognitively unimpaired adults (mean age = 64.2 ± 3.2 years, 65% women), classified into normal glucose tolerance (NGT; hemoglobin A1c [HbA1c] < 5.7%), prediabetes/untreated T2D (HbA1c ≥ 5.7%), and treated T2D groups. Multiple regression analyses assessed group differences in Aβ (18F-florbetaben) and tau (18F-MK-6240) positron emission tomography burden, magnetic resonance imaging-based AD signature cortical thickness, white matter hyperintensity (WMH) volume, and memory performance. Compared to the NGT group, prediabetes/untreated T2D had greater anterior/posterior cingulate and superior parietal cortex Aβ burden, whereas treated T2D had lower cortical thickness and greater WMHs, independent of demographics and apolipoprotein E ε4 status. No group differences were found in tau or memory outcomes. Prediabetes/untreated T2D, but not treated T2D, was associated with early Aβ deposition. Diabetes medications may mitigate brain Aβ burden.

16 June 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
CPCleofé Peña‐Gomez
Cleofé Peña‐Gomez
MAMuge Akinci
Muge Akinci
PYPeter Young
Peter Young
FÖFredrik Öhman
Fredrik Öhman
EPEleni Palpatzis
Eleni Palpatzis
MSMichael Schöll
Michael Schöll
Background: Medial temporal lobe structures are particularly vulnerable in age‐related neurodegenerative diseases. Here, we investigated the brain reorganization that allows maintaining relatively normal global cognitive functioning in patients with herpes simplex encephalitis (HSE) – an infectious neurological disease ‐ with marked focal atrophy most pronounced in the medial temporal lobes, particularly the hippocampus. Using rs‐fMRI we (i) characterized the patterns of functional network organization, and (ii) compared the intra‐/interhemispheric functional connectivity (FC) within each patient.Method: A total of nine HSE patients were included (see Table 1), four of them were affected mainly in the left (LH) and five in the right (RH) hemisphere. The rs‐fMRI data were acquired after a long‐term follow‐up (median 16 years) of the disease and were preprocessed using the AFNI software. For each patient, using different brain parcellations, we computed the intra‐ and inter‐FC strength for each hemisphere separately, yielding four measures of intra‐FC LH/RH and inter‐FC LH/RH . We grouped the subjects according to their lesion‐side and their performance (low, high) in a memory task.Result: We observed, regardless of the lesion side, a highly variable pattern of disrupted FC in each patient. Left‐lesioned patients showed high intra‐FCLH/RH particularly in the precuneus/posterior cingulate (PPC) and the angular gyrus while right‐lesioned patients exhibited a high inter‐FCRH in the medial prefrontal cortex (MPFC) and PPC regions. Both left and right‐lesioned showed decreased intra‐FCLH/RH in ventral medial temporal areas, more pronounced in the left‐lesioned patients (Figure1). Right‐lesioned individuals who showed a pattern of inter‐FC within the right MPF and PPC performed consistently higher on the memory task (percentiles > 50) (Figure2).Conclusion: The substantial HSE‐induced medial temporal lobe lesions induce a global network reorganization. However, the side of the lesion seems to determine a specific pattern of network reorganization that is associated with differential cognitive performance. Left‐lesioned patients exhibited high PPC intra‐ and inter‐FCLH/RH and low memory performance while the right‐lesioned exhibited a high inter‐FCRH on the PPC and MPFC and better memory performance. Left lesions may result in nonadaptive brain reorganizations, however, right lesions, when linked to prefrontal brain reorganizations, may result in cognitive benefits and therefore be adaptive.

31 July 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MAMuge Akinci
Muge Akinci
FAFroogh Aziz
Froogh Aziz
DGDiana Guzman
Diana Guzman
LCLina Cheung
Lina Cheung
JKJian X. Kong
Jian X. Kong
JLJosé A. Luchsinger
José A. Luchsinger
Background and Objectives: Plasma biomarkers, particularly brain-derived phosphorylated-tau (BD-p-tau) species, hold promise as screening tools for Alzheimer’s disease (AD). However, their ability to reflect AD pathology remains understudied in community settings. In a community-based sample, we examined associations between plasma biomarkers and cerebral amyloid (Aβ) deposition, and whether kidney function modified these associations. Methods: This cohort study included cognitively unimpaired, late middle-aged adults with 18 F-Florbetaben PET imaging and NULISAseq-derived plasma biomarker measurements. Analyses were restricted to NULISAseq biomarkers related to AD pathology (Aβ38, Aβ40, Aβ42, ACHE, BACE1, BASP1, BD-p-tau181, BD-p-tau217, CD63, IGFBP7, KLK6, MAPT-tau, PSEN1, SFRP1, total p-tau181, p-tau217, and p-tau231). As a measure of kidney function, cystatin C–based estimated glomerular filtration rate was calculated and categorized by chronic kidney disease (CKD) stage as normal/high (≥90 mL/min/1.73 m 2 ); mildly decreased (60–89 mL/min/1.73 m 2 ); and moderately/severely decreased or failure (<60 mL/min/1.73 m 2 ). Bidirectional stepwise linear regression analysis was performed to identify plasma biomarkers associated with brain Aβ deposition. Linear regression models including plasma biomarker-by-CKD stage interactions tested effect modification by kidney function. Results: A total of 541 Hispanic, non-Hispanic Black, and non-Hispanic White participants were included. Stepwise linear regression retained plasma BD-p-tau217 (B = 0.22; 95% CI 0.19 to 0.25; p < 0.001), which was positively associated with brain Aβ deposition, alongside Aβ42 (B = −0.08; 95% CI −0.11 to −0.06; p < 0.001), IGFBP7 (B = −0.05; 95% CI −0.08 to −0.02; p = 0.004), and BACE1 (B = −0.04; 95% CI −0.07 to −0.01; p = 0.009), which were negatively associated with brain Aβ deposition. A significant BD-p-tau217-by-CKD stage interaction demonstrated a weaker association between BD-p-tau217 and brain Aβ deposition among individuals with moderately/severely decreased kidney function or failure than those with normal/high kidney function (B = −0.17; 95% CI −0.25 to −0.08; p < 0.001). Discussion: In a real-world sample, BD-p-tau217 emerged as the plasma biomarker most strongly associated with brain Aβ deposition, although this association may be attenuated in the presence of moderate/severe kidney dysfunction or kidney failure. IGFBP7 and BACE1 were identified as candidate plasma biomarkers of brain Aβ deposition, warranting replication in independent cohorts.

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
MAMuge Akinci
Muge Akinci
MSMahnaz Shekari
Mahnaz Shekari
EPEleni Palpatzis
Eleni Palpatzis
AEArmand González Escalante
Armand González Escalante
ICIsrael Contador
Israel Contador
EAEider M Arenaza‐Urquijo
Eider M Arenaza‐Urquijo
Background: COVID‐19‐related SARS‐CoV‐2 infection has been linked with brain abnormalities and cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD), neuroinflammation, and neuronal injury. Whether COVID‐19 increases the brain’s vulnerability to the development of AD is unclear. In participants at an increased risk of AD, we investigated the association of COVID‐19 with pre‐ and post‐pandemic AD biomarkers.Method: We included 132 cognitively unimpaired adults from the ALFA+ cohort (52‐71 years, 61.4% women) who provided retrospective self‐reported data on SARS‐CoV‐2 infection (with COVID‐19 vs. without COVID‐19). As of February 2022, 125 (94.7%) participants had available CSF biomarkers (measured with exploratory Roche NeuroToolKit or Elecsys® immunoassays, Roche Diagnostics International Ltd, Rotkreuz, Switzerland) and 76 (57.6%) had [18F]flutemetamol‐PET data acquired before (pre‐pandemic) and after (post‐pandemic) the beginning of the COVID‐19 pandemic (average time lapse between the assessments: 3.5±0.6 years). [18F]flutemetamol PET SUVR maps were obtained using the whole cerebellum as the reference region. First, we performed ANCOVA models to investigate whether COVID‐19 was associated with post‐pandemic CSF biomarkers of core AD pathology (Aβ42/40 and p‐tau), neuronal injury (NfL), and neuroinflammation (sTREM2, GFAP, and IL‐6), while controlling for pre‐pandemic biomarker levels. Covariates were age, sex, years of education, APOE‐ε4 status, and time lapse between the biomarker assessments. Second, we performed a voxel‐wise analysis in SPM‐12 using a matched‐group comparison design (with COVID‐19 vs. without COVID‐19 matched by pre‐pandemic Centiloid values, age, and APOE‐ε4 status) with the post‐pandemic amyloid‐PET scans as the outcome of interest.Result: Fifteen (12%) participants included in ANCOVA reported COVID‐19. Eleven (14.5%) with amyloid‐PET scans reported COVID‐19 and were matched with 11 participants without COVID‐19 for voxel‐wise analysis. In ANCOVA models, no significant association between COVID‐19 and post‐pandemic CSF biomarkers was found (Table 1). Results from the t‐test voxel‐wise analysis also did not show any differences between participants with vs. without COVID‐19 on [18F]flutemetamol‐PET uptake after correction with false discovery rate.Conclusion: Our interim analyses did not show any association between self‐reported COVID‐19 and post‐pandemic biomarkers of AD pathology, neuronal injury, and neuroinflammation. The results are pending confirmation of COVID‐19 status using serology data (n = 181) and complete sample size.